Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Divalproex sodium + Neratinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Divalproex sodium||Depakote||Valproate semisodium|Sodium divalproex||HDAC Inhibitor 38||Depakote (Divalproex sodium) comprises a 1:1 mixture of valproic acid and sodium valproate, which acts as an HDAC inhibitor, potentially resulting in decreased growth and increased apoptosis of tumor cells in combination with other agents (PMID: 25449787, PMID: 20200483). Depakote (divalproex sodium) is FDA approved for treatment of manic episodes associated with bipolar disorder, as well as seizures, and migraines (FDA.gov).|
|Neratinib||Nerlynx||HKI-272|PB272||HER2 Inhibitor 25||Nerlynx (neratinib) inhibits the ERBB2 (HER2) receptor as well as EGFR, resulting in decreased proliferation of HER2 and EGFR expressing tumor cells (PMID: 15173008). Nerlynx (neratinib) is FDA approved for use in patients with early stage ERBB2 (HER2)-positive breast cancer following Herceptin (trastuzumab)-based therapy, and in combination with Xeloda (capecitabine) in patients with advanced/metastatic ERBB2 (HER2)-positive breast cancer who have received two or more anti-ERBB2 (HER2) regimens (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03919292||Phase Ib/II||Divalproex sodium + Neratinib||Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca||Recruiting|